Fiera Capital Corp raised its position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report) by 19.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 29,900 shares of the company’s stock after purchasing an additional 4,783 shares during the quarter. Fiera Capital Corp’s holdings in BeOne Medicines were worth $9,084,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the company. Capital International Sarl increased its position in shares of BeOne Medicines by 2.7% in the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after acquiring an additional 3,956 shares during the period. Capital International Ltd. CA increased its position in shares of BeOne Medicines by 1.4% in the fourth quarter. Capital International Ltd. CA now owns 67,722 shares of the company’s stock valued at $20,575,000 after acquiring an additional 930 shares during the period. Capital International Investors increased its position in shares of BeOne Medicines by 1.3% in the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after acquiring an additional 67,808 shares during the period. Capital Group Investment Management PTE. LTD. increased its position in shares of BeOne Medicines by 2.3% in the fourth quarter. Capital Group Investment Management PTE. LTD. now owns 14,710 shares of the company’s stock valued at $4,469,000 after acquiring an additional 330 shares during the period. Finally, Havemeyer Place LP purchased a new position in shares of BeOne Medicines in the fourth quarter valued at about $501,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.
Wall Street Analyst Weigh In
A number of research firms have issued reports on ONC. Jefferies Financial Group cut shares of BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price objective for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Wells Fargo & Company started coverage on shares of BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 target price on the stock. Finally, Leerink Partners lifted their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.
Insider Buying and Selling at BeOne Medicines
In related news, Director Corazon (Corsee) D. Sanders sold 212 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $309.59, for a total transaction of $65,633.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Margaret Dugan sold 212 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $309.60, for a total transaction of $65,635.20. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 1,641 shares of company stock worth $505,791. Insiders own 6.19% of the company’s stock.
BeOne Medicines Trading Up 0.3%
NASDAQ:ONC opened at $270.80 on Tuesday. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company’s 50-day simple moving average is $301.74 and its 200 day simple moving average is $316.81. The firm has a market capitalization of $29.71 billion, a P/E ratio of 60.58 and a beta of 0.49.
BeOne Medicines (NASDAQ:ONC – Get Free Report) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. As a group, analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.
BeOne Medicines Company Profile
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Featured Stories
- Five stocks we like better than BeOne Medicines
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding ONC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report).
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
